dc.contributor.author |
Siriwardana, R.C. |
en_US |
dc.contributor.author |
Thilakarathne, S. |
en_US |
dc.contributor.author |
Niriella, M.A. |
en_US |
dc.contributor.author |
Dassanayake, A.S. |
en_US |
dc.contributor.author |
Gunetilleke, M.B. |
en_US |
dc.contributor.author |
Habarakada, L.C.A. |
en_US |
dc.contributor.author |
de Silva, H.J. |
en_US |
dc.date.accessioned |
2018-01-02T10:35:02Z |
en_US |
dc.date.available |
2018-01-02T10:35:02Z |
en_US |
dc.date.issued |
2017 |
en_US |
dc.identifier.citation |
BMC Gastroenterology.2017;17(1):142 |
en_US |
dc.identifier.issn |
1471-230X (Electronic) |
|
dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/18572 |
|
dc.description.abstract |
BACKGROUND: Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC). The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear. METHODS: Patients with nvHCC, referred to a Hepatobiliary Clinic from September 2011-2015 were screened. HCC was diagnosed using American Association for the Study of Liver Disease guidelines, and TNM staged. nvHCC was diagnosed when HBsAg and anti-HCVAb was negative. Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated. AFP level was evaluated against patient characteristics, tumour characteristics and survival. RESULTS: Three hundred eighty-nine patients with nvHCC [age 64(12-88) years; 344(88.4%) males] were screened. Median AFP was 25.46 ng/ml (1.16-100,000). 41.2% (n = 160) Of patients had normal AFP level. 22.9% (n = 89) had AFP over 400 ng/ml. Female gender (P < 0.05), vascular invasion (P < 0.001), tumours over 5 cm (P < 0.05), late TNM stage (P < 0.001) and non-surgical candidates had higher AFP levels. Diffuse type (P < 0.001), macro vascular invasion (P < 0.001) and late stage tumours (P < 0.001) had AFP over 400 ng/ml. Having AFP below 400 ng/ml was associated with longer survival (16 vs. 7 months, P < 0.001). CONCLUSION: Pre treatment AFP has a limited value In diagnosing nvHCC, Having a AFP value over 400 ng/ml was associated with aggressive tumour behaviour and poor prognosis. |
en_US |
dc.language.iso |
en_US |
en_US |
dc.publisher |
BioMed Central |
en_US |
dc.subject |
Carcinoma, Hepatocellular |
en_US |
dc.subject |
Carcinoma hepatocellular-aetiology |
en_US |
dc.subject |
Carcinoma, Hepatocellular-therapy |
en_US |
dc.subject |
alpha-Fetoproteins |
en_US |
dc.subject |
Prospective Studies |
en_US |
dc.title |
Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology - a prospective study |
en_US |
dc.type |
Article |
en_US |